Cargando…

ARID1A Alterations Are Associated with FGFR3-Wild Type, Poor-Prognosis, Urothelial Bladder Tumors

Urothelial bladder cancer (UBC) is heterogeneous at the clinical, pathological, genetic, and epigenetic levels. Exome sequencing has identified ARID1A as a novel tumor suppressor gene coding for a chromatin remodeling protein that is mutated in UBC. Here, we assess ARID1A alterations in two series o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Balbás-Martínez, Cristina, Rodríguez-Pinilla, María, Casanova, Ariel, Domínguez, Orlando, Pisano, David G., Gómez, Gonzalo, Lloreta, Josep, Lorente, José A., Malats, Núria, Real, Francisco X.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3641081/ https://www.ncbi.nlm.nih.gov/pubmed/23650517 http://dx.doi.org/10.1371/journal.pone.0062483

Ejemplares similares

Correction: ARID1A Alterations Are Associated with FGFR3-Wild Type, Poor-Prognosis, Urothelial Bladder Tumors
por: Balbás-Martínez, Cristina, et al.
Publicado: (2014)

Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy
por: Balbás-Martínez, Cristina, et al.
Publicado: (2013)

Cyclooxygenase-2 Expression in Bladder Cancer and Patient Prognosis: Results from a Large Clinical Cohort and Meta-Analysis
por: Czachorowski, Maciej J., et al.
Publicado: (2012)

FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder
por: Guancial, Elizabeth A, et al.
Publicado: (2014)

FGFR3 Alterations in the Era of Immunotherapy for Urothelial Bladder Cancer
por: Kacew, Alec, et al.
Publicado: (2020)

Transcriptomic analysis of micropapillary high grade T1 urothelial bladder cancer
por: Bowden, Michaela, et al.
Publicado: (2020)

Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
por: Facchinetti, Francesco, et al.
Publicado: (2023)

Role of FGFR3 in Urothelial Carcinoma
por: Akanksha, Malik, et al.
Publicado: (2019)

ARID1A upregulation predicts better survival in patients with urothelial bladder carcinoma
por: Cao, Qifeng, et al.
Publicado: (2019)

Expression of ARID1B Is Associated With Poor Outcomes and Predicts the Benefit from Adjuvant Chemotherapy in Bladder Urothelial Carcinoma
por: Wang, Beihe, et al.
Publicado: (2017)

Complexity of FGFR signalling in metastatic urothelial cancer
por: Rodriguez-Vida, Alejo, et al.
Publicado: (2015)

Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial Carcinoma
por: Benjamin, David J, et al.
Publicado: (2022)

ARID1A-deficiency in urothelial bladder cancer: No predictive biomarker for EZH2-inhibitor treatment response?
por: Garczyk, Stefan, et al.
Publicado: (2018)

Targeting the Src Pathway Enhances the Efficacy of Selective FGFR Inhibitors in Urothelial Cancers with FGFR3 Alterations
por: Lima, Nadia Carvalho, et al.
Publicado: (2020)

Fibroblast Growth Factor Receptor (FGFR) Inhibitors in Urothelial Cancer
por: Garje, Rohan, et al.
Publicado: (2020)

Genetic Variation in the TP53 Pathway and Bladder Cancer Risk. A Comprehensive Analysis
por: Pineda, Silvia, et al.
Publicado: (2014)

BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression
por: Kim, Se Hyun, et al.
Publicado: (2018)

ASP5878, a selective FGFR inhibitor, to treat FGFR3‐dependent urothelial cancer with or without chemoresistance
por: Kikuchi, Aya, et al.
Publicado: (2017)

Treatment approaches for FGFR-altered urothelial carcinoma: targeted therapies and immunotherapy
por: Benjamin, David J., et al.
Publicado: (2023)

The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies
por: Earl, Julie, et al.
Publicado: (2015)

Integration Analysis of Three Omics Data Using Penalized Regression Methods: An Application to Bladder Cancer
por: Pineda, Silvia, et al.
Publicado: (2015)

Prediction of non-muscle invasive bladder cancer outcomes assessed by innovative multimarker prognostic models
por: López de Maturana, E., et al.
Publicado: (2016)

Case Report: Anlotinib Combined With Sintilimab as Third-Line Treatment in a Metastatic Urothelial Bladder Carcinoma Patient With FGFR3 Mutation
por: Cao, Jian-zhou, et al.
Publicado: (2021)

The impact of mutational clonality in predicting the response to immune checkpoint inhibitors in advanced urothelial cancer
por: Boll, Lilian Marie, et al.
Publicado: (2023)

Erratum to: The UBC-40 Urothelial Bladder Cancer Cell Line Index: a genomic resource for functional studies
por: Earl, Julie, et al.
Publicado: (2015)

Erratum to: The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies
por: Earl, Julie, et al.
Publicado: (2016)

Immunohistochemistry-Based Taxonomical Classification of Bladder Cancer Predicts Response to Neoadjuvant Chemotherapy
por: Font, Albert, et al.
Publicado: (2020)

Involvement of FGFR4 Gene Variants on the Clinicopathological Severity in Urothelial Cell Carcinoma
por: Tsay, Ming-Dow, et al.
Publicado: (2019)

Development of resistance to FGFR inhibition in urothelial carcinoma via multiple pathways in vitro
por: Pettitt, Geoffrey A, et al.
Publicado: (2022)

Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer
por: Weickhardt, Andrew J., et al.
Publicado: (2022)

Outcomes of poorly differentiated and plasmacytoid variant bladder urothelial carcinoma
por: Lockhart, Kathleen, et al.
Publicado: (2021)

FGFR2/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinoma
por: Adib, Elio, et al.
Publicado: (2021)

Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma
por: Lyou, Yung, et al.
Publicado: (2022)

A Novel Methylation Marker NRN1 plus TERT and FGFR3 Mutation Using Urine Sediment Enables the Detection of Urothelial Bladder Carcinoma
por: Zhang, Junjie, et al.
Publicado: (2023)

Tackling FGFR3-driven bladder cancer with a promising synergistic FGFR/HDAC targeted therapy
por: Wang, Zechen, et al.
Publicado: (2023)

Characterization of the tumor-infiltrating immune repertoire in muscle invasive bladder cancer
por: Benítez, Raquel, et al.
Publicado: (2023)

Oncogenic FGFR3 gene fusions in bladder cancer
por: Williams, Sarah V., et al.
Publicado: (2013)

Targetable Pathways in Advanced Bladder Cancer: FGFR Signaling
por: Xiao, Jin-Fen, et al.
Publicado: (2021)

Pure Large Nested Variant of Urothelial Carcinoma (LNUC) Is the Prototype of an FGFR3 Mutated Aggressive Urothelial Carcinoma with Luminal-Papillary Phenotype
por: Weyerer, Veronika, et al.
Publicado: (2020)

Mandibular Metastasis of a Recurrent Poorly Differentiated Urothelial Bladder Carcinoma
por: Aoun, Georges, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_r6t1rh1qgja8epp2450cjk46jk